Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Maxwell T. Vergo
Based on 1 article published since 2010
(Why 1 article?)
||||

Between 2010 and 2020, Maxwell T. Vergo wrote the following article about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. 2016

Reddy, Sangeetha M / Vergo, Maxwell T / Paice, Judith A / Kwon, Nancy / Helenowski, Irene B / Benson, Al B / Mulcahy, Mary F / Nimeiri, Halla S / Harden, Robert N. ·Division of Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: smreddy1@mdanderson.org. · Geisel School of Medicine, Section of Palliative Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH. · Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. · Department of Biobehavioral Sciences, Columbia University, New York, NY. · Department of Preventive Medicine, Northwestern University, Chicago, IL. · Center for Pain Studies, Rehabilitation Institute of Chicago and Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL. ·Clin Colorectal Cancer · Pubmed #26337211.

ABSTRACT: PURPOSE: Oxaliplatin neurotoxicity has a spectrum of manifestations from an often reversible acute neurotoxicity to a more irreversible "stocking and glove" chronic neuropathy that is associated with high morbidity. Quantitative sensory testing (QST) is a noninvasive psychometric testing method that can potentially be used in the clinic setting to measure subclinical neurologic changes early on to identify patients that will experience chronic oxaliplatin-induced peripheral neuropathy at 1 year. PATIENTS AND METHODS: Thirty patients with gastrointestinal malignancies who were receiving oxaliplatin were recruited. QST and patient-reported outcomes were assessed at baseline; during infusion cycles 1, 2, 4, and 6; and at 1 year. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, chronic neuropathy scores were assessed at the 1-year time point. The variables at each time point were evaluated for prediction of 1-year chronic neuropathy scores. RESULTS: We found that patients with preexisting subclinical neuropathy were more likely to experience grades 2 and 3 chronic neuropathy than were those who did not have this condition (heat detection threshold, Spearman correlation coefficient (rs) = 0.39; P = .037; pellet retrieval time, rs = 0.47; P = .024). Patients in whom thermal and cutaneous sensory deficits developed with cycle 1 infusion were also more likely to experience grades 2 and 3 neuropathy at 1 year (cold detection threshold, rs = 0.50; P = .007; heat detection threshold, rs = 0.39; P = .042; cutaneous detection threshold, rs = 0.42; P = .043). CONCLUSION: QST provides a noninvasive, commercially available, and feasible clinical test to select patients, even before oxaliplatin treatment, who are likely to experience moderate to severe chronic peripheral neuropathy.